Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
Dow
McKinsey
Colorcon

Last Updated: May 22, 2022

Details for New Drug Application (NDA): 021446


✉ Email this page to a colleague

« Back to Dashboard

NDA 021446 describes LYRICA, which is a drug marketed by Upjohn and is included in three NDAs. It is available from nine suppliers. There are three patents protecting this drug and six Paragraph IV challenges. Additional details are available on the LYRICA profile page.

The generic ingredient in LYRICA is pregabalin. There are forty-one drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.
Summary for 021446
Tradename:LYRICA
Applicant:Upjohn
Ingredient:pregabalin
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021446
Suppliers and Packaging for NDA: 021446
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LYRICA pregabalin CAPSULE;ORAL 021446 NDA Parke-Davis Div of Pfizer Inc 0071-1012 0071-1012-68 90 CAPSULE in 1 BOTTLE (0071-1012-68)
LYRICA pregabalin CAPSULE;ORAL 021446 NDA Parke-Davis Div of Pfizer Inc 0071-1013 0071-1013-41 100 BLISTER PACK in 1 CARTON (0071-1013-41) > 1 CAPSULE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength25MG
Approval Date:Dec 30, 2004TE:ABRLD:Yes
Regulatory Exclusivity Expiration:May 23, 2022
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Nov 23, 2022
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:Dec 30, 2004TE:ABRLD:Yes
Regulatory Exclusivity Expiration:May 23, 2022
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Expired US Patents for NDA 021446

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-005 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-002 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-001 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-008 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-007 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
Upjohn LYRICA pregabalin CAPSULE;ORAL 021446-004 Dec 30, 2004 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
McKesson
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.